TR200000756T2 - Davranış bozukluğu tedavisi. - Google Patents

Davranış bozukluğu tedavisi.

Info

Publication number
TR200000756T2
TR200000756T2 TR2000/00756T TR200000756T TR200000756T2 TR 200000756 T2 TR200000756 T2 TR 200000756T2 TR 2000/00756 T TR2000/00756 T TR 2000/00756T TR 200000756 T TR200000756 T TR 200000756T TR 200000756 T2 TR200000756 T2 TR 200000756T2
Authority
TR
Turkey
Prior art keywords
treatment
behavioral disorder
behavioral
disorder
reuptake inhibitors
Prior art date
Application number
TR2000/00756T
Other languages
English (en)
Inventor
Harrison Heiligenstein John
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR200000756T2 publication Critical patent/TR200000756T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Norepinefrini geri alma inhibitörleri davranis bozuklugunun tedavisinde kullanilmaktadirlar.
TR2000/00756T 1997-09-23 1998-09-01 Davranış bozukluğu tedavisi. TR200000756T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5962897P 1997-09-23 1997-09-23

Publications (1)

Publication Number Publication Date
TR200000756T2 true TR200000756T2 (tr) 2000-09-21

Family

ID=22024194

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00756T TR200000756T2 (tr) 1997-09-23 1998-09-01 Davranış bozukluğu tedavisi.

Country Status (17)

Country Link
US (1) US6184222B1 (tr)
EP (1) EP0919235A1 (tr)
JP (1) JP2001517619A (tr)
KR (1) KR20010024219A (tr)
CN (2) CN1271278A (tr)
AU (1) AU740192B2 (tr)
BR (1) BR9812371A (tr)
CA (1) CA2304657C (tr)
EA (1) EA002804B1 (tr)
HU (1) HUP0004025A3 (tr)
IL (1) IL134718A0 (tr)
NO (1) NO20001479L (tr)
NZ (1) NZ502853A (tr)
PL (1) PL339425A1 (tr)
TR (1) TR200000756T2 (tr)
UA (1) UA57107C2 (tr)
WO (1) WO1999015163A1 (tr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1071425T3 (da) * 1998-04-24 2007-12-27 Scarista Ltd Behandling af depression og farmaceutiske præparater dertil
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
KR100717660B1 (ko) 1999-07-01 2007-05-15 파마시아 앤드 업존 캄파니 엘엘씨 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
AU2005220235B2 (en) * 1999-07-01 2007-05-10 Pharmacia & Upjohn Company Selective norepinephrine reuptake inhibitors and methods of using the same
DK1500396T3 (da) * 1999-07-01 2005-12-19 Pharmacia & Upjohn Co Llc Reboxetin til behandling af migrænehovedpiner
CO5210862A1 (es) * 1999-09-15 2002-10-30 Alza Corp Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
US20050096396A1 (en) * 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
AU2002311784B2 (en) * 2001-03-29 2007-11-22 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US6613763B2 (en) * 2001-04-20 2003-09-02 Mgi Applied Genomics Use of molindone to treat oppositional defiant disorder and conduct disorder
ATE433163T1 (de) * 2001-07-11 2009-06-15 Cns Response Inc Verfahren zur vorhersage der behandlungsresultate
US6700018B2 (en) * 2001-07-17 2004-03-02 Mayo Foundation For Medical Education And Research Amine compounds and inhibiting neurotransmitter reuptake
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
WO2003068211A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
PT1485078E (pt) * 2002-03-15 2013-01-14 Cypress Bioscience Inc Milnacipran para o tratamento do síndrome do intestino irritável
US20040034083A1 (en) * 2002-04-18 2004-02-19 Stephenson Diane T. Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s)
MXPA04011916A (es) * 2002-06-17 2005-03-31 Pharmacia Italia Spa Sales farmaceuticas de reboxetina.
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US6943193B1 (en) * 2003-01-21 2005-09-13 Jordan A. Altabet Method for treating sexual dysfunction
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
RU2317817C2 (ru) * 2003-02-14 2008-02-27 Пьер Фабр Медикаман Применение (1s,2r) энантиомера милнаципрана для получения лекарственного средства
US20070032554A1 (en) * 2003-08-27 2007-02-08 Elililly And Company A Corporation Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
WO2005060968A1 (en) 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
EP1715856B1 (en) * 2003-12-31 2012-07-11 Actavis Group PTC ehf. Atomoxetine formulations
US20080200556A1 (en) * 2004-06-07 2008-08-21 Mayo Foundation For Medical Education And Research Amine Compounds And Inhibiting Neurotrasmitter Reuptake
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20080031932A1 (en) * 2006-08-04 2008-02-07 Watson Laboratories, Inc. Transdermal atomoxetine formulations and associated methods
US8440724B2 (en) * 2008-01-09 2013-05-14 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
WO2011057176A1 (en) * 2009-11-06 2011-05-12 Forest Laboratories Holding Limited Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
US9944618B2 (en) 2013-03-14 2018-04-17 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
CN115160988B (zh) * 2013-04-30 2024-05-14 Ａｇｃ株式会社 包含三氟乙烯的组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2061665C (en) * 1991-02-25 2002-04-16 Mark Mortensen Foreman Treatment of lower urinary tract disorders
DK0537915T3 (da) * 1991-09-27 1995-11-27 Lilly Co Eli N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin
ZA93694B (en) * 1993-02-01 1993-06-03 Lilly Co Eli Pharmaceutical treatments.
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
CA2227410A1 (en) * 1995-07-24 1997-02-06 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US5696168A (en) * 1995-07-24 1997-12-09 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder

Also Published As

Publication number Publication date
NO20001479D0 (no) 2000-03-22
CA2304657A1 (en) 1999-04-01
UA57107C2 (uk) 2003-06-16
EA200000351A1 (ru) 2000-10-30
JP2001517619A (ja) 2001-10-09
CN1762338A (zh) 2006-04-26
PL339425A1 (en) 2000-12-18
US6184222B1 (en) 2001-02-06
HUP0004025A2 (hu) 2002-01-28
NO20001479L (no) 2000-03-22
AU740192B2 (en) 2001-11-01
AU9041798A (en) 1999-04-12
CA2304657C (en) 2005-10-25
HUP0004025A3 (en) 2002-02-28
KR20010024219A (ko) 2001-03-26
EA002804B1 (ru) 2002-10-31
CN1271278A (zh) 2000-10-25
EP0919235A1 (en) 1999-06-02
IL134718A0 (en) 2001-04-30
NZ502853A (en) 2002-08-28
WO1999015163A1 (en) 1999-04-01
BR9812371A (pt) 2000-09-19

Similar Documents

Publication Publication Date Title
TR200000756T2 (tr) Davranış bozukluğu tedavisi.
ES2182906T3 (es) Grapa quirurgica helicoidal.
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
RS50005B (sr) Novi oblik s-omeprazola
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
TR199501053A2 (tr) Tedavide yararli spiro-azabisiklik bilesikler.
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
TR199801255T2 (tr) Vitronektin reseptör antagonistleri.
TR199501472A2 (tr) Matriks metaloproteaz inhibitörler.
TR200000374T2 (tr) Akut akciğer harabiyeti ve fibrozitinin alfavbeta6 antagonistleriyle tedavisi.
TR199600358A2 (tr) -Adrenerjik agonistleri.
SE9904377D0 (sv) Pharmaceutical combinations
ATE254917T1 (de) Mittel gegen parasitäre protozoen
FI955159A0 (fi) Kaviotyyny
ATE228760T1 (de) Thrombininhibitoren
PT888330E (pt) Metodos de tratamento ou prevencao de cistite intersticial
FR2716375B3 (fr) Injecteur médical.
ATE215084T1 (de) Imidazopyridin-azolidinone
NO20005548D0 (no) Mykobakterieinhibitorer
PT1052991E (pt) Utilizacao de loperamida para o tratamento de infeccoes microbianas
BR9801839A (pt) Medicamento analgésico e aplicação de (+) -0-demetiltramadol.
PT1017377E (pt) Utilizacao de 2-aminotetralinas 6,7-substituidas para o tratamento de condicoes inflamatorias mediadas por citoquina
IT1288138B1 (it) Dispositivo per la costruzione di semigusci rivestiti, in particolare per custodie di occhiali, o similli.
IT239627Y1 (it) Struttura di punto informativo, particolarmente per la consultazionepubblica di informazioni.